Literature DB >> 30630206

How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors.

Emmanuel J Favaloro1,2, Geoffrey Kershaw2, Soma Mohammed1, Giuseppe Lippi3,4.   

Abstract

The activated partial thromboplastin time (APTT) assay is a very common coagulation test, used for several reasons. The test is conventionally used for assessing the contact factor (intrinsic) pathway of blood coagulation, and thus for screening deficiencies in this pathway, most typically factors VIII, IX, and XI. The APTT is also sensitive to contact factor deficiencies, including factor XII, prekallikrein, and high-molecular-weight kininogen. The APTT may also be elevated in a variety of conditions, including liver disease, vitamin K deficiency, and disseminated intravascular coagulation. The APTT can also be used for monitoring unfractionated heparin (UFH) therapy, as well as for screening lupus anticoagulant (LA) or for assessing thrombosis risk. Which of these separate uses is important to a given laboratory or clinician depends on the laboratory and the clinical context. For example, UFH sensitivity is important in hospital-based laboratories, where UFH therapy is used, but not in hospital-based laboratories where low-molecular-weight heparin (LMWH) is largely employed or where UFH may be assessed by anti-factor Xa testing, or in private/community laboratories not associated with a hospital system. High sensitivity to (low levels of) factors VIII, IX, and XI is generally preferred, as their deficiencies are clinically significant. Also preferred, but not usually achieved, is low sensitivity to factor XII and other contact factors, as these deficiencies are usually asymptomatic. Nevertheless, a good knowledge of factor sensitivity is usually needed, if only to help explain the reasons for a prolonged APTT in a given patient, or whether factor testing or other investigation is required. A good working knowledge of reagents sensitivity to LA is also advisable, especially when the reagent is used as part of a LA test panel, or else as a "general-purpose screening reagent." The current report is aimed at providing some guidance around these questions, and is intended as a kind of "how to" guide, that will enable laboratories to assess APTT reagents in regard to their sensitivity to heparin, LA, and clotting factors. The report also provides some advice on generation of normal reference ranges, as well as solutions for troubleshooting prolonged APTTs, when performing factor testing or searching for inhibitors. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30630206     DOI: 10.1055/s-0038-1677018

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  14 in total

1.  Cryptogenic oozers and bruisers.

Authors:  Kristi J Smock; Karen A Moser
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 2.  Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances.

Authors:  Arne Vandevelde; Katrien M J Devreese
Journal:  J Clin Med       Date:  2022-04-13       Impact factor: 4.964

3.  Assessment and establishment of a reference interval for Roche Cobas t 711 coagulation analyzer for a hospital in China.

Authors:  Chi Zhu; Lili Sun; Haowei Li; Zhenghua Dong; Siyuan Yu; Xiaoming Zhao; Ji Yang; Wenjuan Wu
Journal:  Pract Lab Med       Date:  2022-02-17

4.  Uncontrollable bleeding after tooth extraction from asymptomatic mild hemophilia patients: two case reports.

Authors:  Guo Fan; Yi Shen; Yu Cai; Ji-Hong Zhao; Yang Wu
Journal:  BMC Oral Health       Date:  2022-03-13       Impact factor: 2.757

Review 5.  Antithrombotic and anticoagulation therapies in cardiogenic shock: a critical review of the published literature.

Authors:  Razvan I Radu; Tuvia Ben Gal; Magdy Abdelhamid; Elena-Laura Antohi; Marianna Adamo; Andrew P Ambrosy; Oliviana Geavlete; Yuri Lopatin; Alexander Lyon; Oscar Miro; Marco Metra; John Parissis; Sean P Collins; Stefan D Anker; Ovidiu Chioncel
Journal:  ESC Heart Fail       Date:  2021-10-19

Review 6.  Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants.

Authors:  Emmanuel J Favaloro; Leonardo Pasalic
Journal:  Res Pract Thromb Haemost       Date:  2022-03-15

7.  Should multiple factor dilutions be performed for all patient coagulation factor assays? Let the debate begin!

Authors:  Emmanuel J Favaloro; Leonardo Pasalic
Journal:  Res Pract Thromb Haemost       Date:  2022-03-13

8.  Gender-specific differences in haemostatic parameters and their influence on blood loss in bimaxillary surgery.

Authors:  Michael Schwaiger; Sarah-Jayne Edmondson; Jasmin Rabensteiner; Florian Prüller; Thomas Gary; Wolfgang Zemann; Jürgen Wallner
Journal:  Clin Oral Investig       Date:  2022-01-11       Impact factor: 3.573

9.  Evaluation of Anti-Activated Factor X Activity and Activated Partial Thromboplastin Time Relations and Their Association with Bleeding and Thrombosis during Veno-Arterial ECMO Support: A Retrospective Study.

Authors:  Mouhamed Djahoum Moussa; Jérôme Soquet; Antoine Lamer; Julien Labreuche; Guillaume Gantois; Annabelle Dupont; Osama Abou-Arab; Natacha Rousse; Vincent Liu; Caroline Brandt; Valentin Foulon; Guillaume Leroy; Guillaume Schurtz; Emmanuel Jeanpierre; Alain Duhamel; Sophie Susen; André Vincentelli; Emmanuel Robin
Journal:  J Clin Med       Date:  2021-05-17       Impact factor: 4.241

10.  Reporting of activated partial thromboplastin time (aPTT): Could we achieve better comparability of the results?

Authors:  Ana Bronić; Sandra Margetić; Desiree Coen Herak; Marija Milić; Branka Krešić; Vanja Radišić Biljak; Jasna Leniček Krleža
Journal:  Biochem Med (Zagreb)       Date:  2021-06-15       Impact factor: 2.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.